JP2018512406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512406A5 JP2018512406A5 JP2017548980A JP2017548980A JP2018512406A5 JP 2018512406 A5 JP2018512406 A5 JP 2018512406A5 JP 2017548980 A JP2017548980 A JP 2017548980A JP 2017548980 A JP2017548980 A JP 2017548980A JP 2018512406 A5 JP2018512406 A5 JP 2018512406A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- stereoisomer
- pharmaceutically acceptable
- diastereomer
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 19
- -1 alkyl carboxylic acids Chemical class 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 206010016654 Fibrosis Diseases 0.000 claims 8
- 230000004761 fibrosis Effects 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 5
- 150000004677 hydrates Chemical class 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 claims 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000001934 delay Effects 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001188 haloalkyl group Chemical class 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 C*C(C(N1)=O)NC1=O Chemical compound C*C(C(N1)=O)NC1=O 0.000 description 2
- LMRLPPWNVOYTCQ-UHFFFAOYSA-N CC(C)C(C(C)(N1)O)OC1=O Chemical compound CC(C)C(C(C)(N1)O)OC1=O LMRLPPWNVOYTCQ-UHFFFAOYSA-N 0.000 description 1
- SSMDYRHBKZVGNR-UHFFFAOYSA-N CC(C)C(C(N1)=O)=CC1=O Chemical compound CC(C)C(C(N1)=O)=CC1=O SSMDYRHBKZVGNR-UHFFFAOYSA-N 0.000 description 1
- GGMXVSSJODBBQA-UHFFFAOYSA-N CC(C)C(O1)=CNC1=O Chemical compound CC(C)C(O1)=CNC1=O GGMXVSSJODBBQA-UHFFFAOYSA-N 0.000 description 1
- GAIOQBNXIHMNHE-UHFFFAOYSA-N CC(C)CC(C(F)(F)F)N Chemical compound CC(C)CC(C(F)(F)F)N GAIOQBNXIHMNHE-UHFFFAOYSA-N 0.000 description 1
- KAJJUFUPJGVIFJ-UHFFFAOYSA-N CC(CC(N1)=O)C1=O Chemical compound CC(CC(N1)=O)C1=O KAJJUFUPJGVIFJ-UHFFFAOYSA-N 0.000 description 1
- GOZPJNMFUQYVMU-UHFFFAOYSA-N COCc(cc(cc1)-c2ccccc2)c1-c1cccc(O)c1 Chemical compound COCc(cc(cc1)-c2ccccc2)c1-c1cccc(O)c1 GOZPJNMFUQYVMU-UHFFFAOYSA-N 0.000 description 1
- QRXBBEOQXMPBDN-BPNWFJGMSA-N C[C@H](CC(OC1Cc(cc(cc2)-c3ccccc3)c2-c2cccc([O]=C)c2)=O)C1=O Chemical compound C[C@H](CC(OC1Cc(cc(cc2)-c3ccccc3)c2-c2cccc([O]=C)c2)=O)C1=O QRXBBEOQXMPBDN-BPNWFJGMSA-N 0.000 description 1
- UWNJCWROXGRALG-UHFFFAOYSA-N OCCc(cc(cc1)-c2ccccc2)c1-c1cccc(O)c1 Chemical compound OCCc(cc(cc1)-c2ccccc2)c1-c1cccc(O)c1 UWNJCWROXGRALG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015900979A AU2015900979A0 (en) | 2015-03-18 | Compositions for the treatment of fibrosis | |
| AU2015900979 | 2015-03-18 | ||
| PCT/AU2016/000095 WO2016145479A1 (en) | 2015-03-18 | 2016-03-18 | Compositions for the treatment of fibrosis and fibrosis-related conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512406A JP2018512406A (ja) | 2018-05-17 |
| JP2018512406A5 true JP2018512406A5 (enExample) | 2019-04-11 |
| JP6734294B2 JP6734294B2 (ja) | 2020-08-05 |
Family
ID=56918156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548980A Active JP6734294B2 (ja) | 2015-03-18 | 2016-03-18 | 線維症及び線維症に関連する状態の処置のための組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10035775B2 (enExample) |
| EP (1) | EP3271320B1 (enExample) |
| JP (1) | JP6734294B2 (enExample) |
| KR (1) | KR102591689B1 (enExample) |
| CN (1) | CN107531598B (enExample) |
| AU (1) | AU2016232978B2 (enExample) |
| BR (1) | BR112017019824B1 (enExample) |
| CA (1) | CA2979413C (enExample) |
| DK (1) | DK3271320T3 (enExample) |
| ES (1) | ES2766769T3 (enExample) |
| IL (1) | IL254505A0 (enExample) |
| MX (1) | MX375918B (enExample) |
| MY (1) | MY182818A (enExample) |
| NZ (1) | NZ736164A (enExample) |
| PH (1) | PH12017501694B1 (enExample) |
| RU (1) | RU2712140C2 (enExample) |
| SG (1) | SG11201707561RA (enExample) |
| WO (1) | WO2016145479A1 (enExample) |
| ZA (1) | ZA201706985B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3353147B1 (en) * | 2015-09-22 | 2021-01-13 | Vectus Biosystems Limited | Synthesis of terphenyl compounds |
| BR112019001510B1 (pt) * | 2016-07-28 | 2022-11-08 | Vectus Biosystems Limited | Composto, e, uso de um composto para manufatura de um medicamento para tratar profilática ou terapeuticamente fibrose pulmonar, ou uma enfermidade relacionada em um indivíduo com fibrose pulmonar ou em risco de desenvolver fibrose pulmonar |
| JP7901085B2 (ja) * | 2021-01-13 | 2026-08-05 | フォスティン・セラピューティクス | 線維性疾患を治療するための環式オキサホスフィナン化合物及びそのアナログ |
| CN118994235A (zh) * | 2023-05-19 | 2024-11-22 | 南京工业大学 | 一种β-三氟甲基取代α，β-不饱和磷酸酯及膦氧化合物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006322656B2 (en) * | 2005-12-09 | 2012-03-08 | Vectus Biosystems Limited | VIP fragments and methods of use |
| FR2904827B1 (fr) * | 2006-08-11 | 2008-09-19 | Sanofi Aventis Sa | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii |
| US20120088737A2 (en) * | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
| MX368865B (es) * | 2013-09-17 | 2019-08-02 | Vectus Biosystems Ltd | Composiciones para el tratamiento de hipertension y/o fibrosis. |
| US9630935B2 (en) * | 2013-09-17 | 2017-04-25 | Vectus Biosystems Limited | Compositions for the treatment of hypertension and/or fibrosis |
-
2016
- 2016-03-18 SG SG11201707561RA patent/SG11201707561RA/en unknown
- 2016-03-18 KR KR1020177030092A patent/KR102591689B1/ko active Active
- 2016-03-18 MY MYPI2017001348A patent/MY182818A/en unknown
- 2016-03-18 WO PCT/AU2016/000095 patent/WO2016145479A1/en not_active Ceased
- 2016-03-18 DK DK16764055.6T patent/DK3271320T3/da active
- 2016-03-18 US US15/557,762 patent/US10035775B2/en active Active
- 2016-03-18 BR BR112017019824-0A patent/BR112017019824B1/pt active IP Right Grant
- 2016-03-18 ES ES16764055T patent/ES2766769T3/es active Active
- 2016-03-18 EP EP16764055.6A patent/EP3271320B1/en active Active
- 2016-03-18 NZ NZ736164A patent/NZ736164A/en unknown
- 2016-03-18 JP JP2017548980A patent/JP6734294B2/ja active Active
- 2016-03-18 RU RU2017135950A patent/RU2712140C2/ru active
- 2016-03-18 MX MX2017011904A patent/MX375918B/es active IP Right Grant
- 2016-03-18 CA CA2979413A patent/CA2979413C/en active Active
- 2016-03-18 AU AU2016232978A patent/AU2016232978B2/en active Active
- 2016-03-18 PH PH1/2017/501694A patent/PH12017501694B1/en unknown
- 2016-03-18 CN CN201680028430.1A patent/CN107531598B/zh active Active
-
2017
- 2017-09-14 IL IL254505A patent/IL254505A0/en active IP Right Grant
- 2017-10-16 ZA ZA2017/06985A patent/ZA201706985B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2018000130A1 (en) | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| CR20220105A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| JP2014503574A5 (enExample) | ||
| EP4574210A3 (en) | Kappa opioid receptor antagonists and products and methods related thereto | |
| ZA202006378B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| JP2015537020A5 (enExample) | ||
| WO2006069155A3 (en) | Inhibitors of protein arginine methyl transferases | |
| JP2015500326A5 (enExample) | ||
| WO2017176620A3 (en) | SOLUBLE C5aR ANTAGONISTS | |
| CL2019003857A1 (es) | Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas. | |
| JP2013542261A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2014129360A5 (enExample) | ||
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| JP2019535723A5 (enExample) | ||
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| MX2019013275A (es) | Inhibidores de la quinasa 1 reguladora de la señal de apoptosis y métodos de uso de estos. | |
| JP2017525717A5 (enExample) | ||
| JP2015502371A5 (enExample) | ||
| CA3155875A1 (en) | BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE | |
| JP2016531846A5 (enExample) | ||
| RU2017135950A (ru) | Композиции для лечения фиброза и связанных с фиброзом состояний | |
| WO2018071315A3 (en) | Piperidine derivatives as liver x receptor beta agonists, compositions, and their use | |
| JP2022515272A5 (enExample) |